Methods Study Design and Participants The Atopic Dermatitis Anti-IgE Pediatric Trial (ADAPT) was a single-center, double-blind, parallel-group, placebo-controlled randomized clinical trial that compared anti-IgE medication (omalizumab) with placebo to treat severe eczema in children with atopy. It wa...
Patients who had used any systemic JAK inhibitor, had used a systemic corticosteroid within 4 weeks of the first dose of study medication, had used topical treatments for AD within 72 hours of the first dose of study medication, or had received treatment with dupilumab within 6 weeks of the ...
*Responders were defined as those achieving a 75% reduction in the Eczema Area and Severity Index from baseline (EASI-75) or an IGA 0 or 1 (“clear” or “almost clear”) with at least 2-point improvement and without rescue medication use at Week 16....
the medication is working; they just thought that it was going to lead to a cure, so when they discontinue it, the disease comes back, so we need to get a sense of the family’s belief systems and what they are willing to accept. And we don’t want to overwhelm them right away...
My number one piece of health advice for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients, more important than any current medication or treatment, is to never exceed your energy limit. Let me explain to be clear. The most unique, best identifying symptom of Chronic Fatigue Syndrome/Myalg...
Rescue medication was initiated in the BE period for 12 of 281 (4.3%), 15 of 285 (5.3%), 2 of 121 (1.7%), and 1 of 123 (0.8%) patients receiving upadacitinib 15 mg, upadacitinib 30 mg, placebo/upadacitinib 15 mg, and placebo/upadacitinib 30 mg, respectively, in Measure ...
Efficacy analyses used the modified intent-to-treat population (all patients who were randomized and received study drug regardless of rescue medication use). Safety analyses used the safety population (those randomized who received ≥1 dose of study drug). The primary end point was evaluated using...
placebo-controlled study JADE TEEN was conducted in countries of the Asia–Pacific region, Europe, and North America in patients aged 12 to 17 years with moderate-to-severe AD and an inadequate response to 4 consecutive weeks or longer of topical medication or a need for systemic therapy for ...